“Speculative But Promising”: A Newly IPO-ed Biotech With A Very Different Approach To Psychedelics

When it comes to treating mental illnesses, the author of today’s article notes that “New therapies derived from psychedelic compounds…are offering hope, not to mention a slew of opportunities for forward-thinking investors.” He proceeds to highlight one such opportunity: a newly IPO-ed biotech that’s currently the largest biotech focusing on the development of psychedelic therapies – and which is taking a very different approach to psychedelics from its competitors. For more on this “speculative but promising” stock, CLICK HERE.